Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
Mycobacterium bovis bacillus Calmette–Guerin (BCG) remains at the forefront of immunotherapy for treating bladder cancer patients. However, the incidence of recurrence and progression to invasive cancer is commonly observed. There are no established effective intravesical therapies available for pat...
Main Authors: | Julieti Huch Buss, Karine Rech Begnini, Camila Bonemann Bender, Adriana R. Pohlmann, Silvia S. Guterres, Tiago Collares, Fabiana Kömmling Seixas |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00977/full |
Similar Items
-
LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS
by: M. M. Zorina, et al.
Published: (2016-10-01) -
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
by: Vivek Sharma, et al.
Published: (2020-12-01) -
Evaluating the need for transurethral bladder biopsy at first follow up after intravesical BCG therapy for superficial bladder cancer: Preliminary data
by: K. Mursi, et al.
Published: (2012-03-01) -
Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect
by: Jiansong Han, et al.
Published: (2020-09-01) -
BCG Induced Necrosis of the Entire Bladder Urothelium
by: Malte Krönig, et al.
Published: (2015-09-01)